VENTOLIN
LOE ApproachingNDAINHALATIONAEROSOL, METEREDPriority Review
Approved
May 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
VENTOLIN by GSK is 2 -adrenergic receptors compared with isoproterenol. Approved for exercise-induced bronchospasm in adult, older. First approved in 1981.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENTOLIN is a metered-dose inhaled aerosol containing albuterol (salbutamol), a rapid-acting beta-2 agonist bronchodilator. It is used to treat acute bronchospasm and as a rescue medication for patients with asthma and chronic obstructive pulmonary disease (COPD). The drug works by stimulating beta-2 adrenergic receptors in airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost management and defending market share rather than growth initiatives.
Mechanism of Action
2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50%…
Indications (2)
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.